sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
|
cocaine
|
norepinephrine
|
EFFECT
|
7798493.xml
|
DDI-MedLine.d94.s12
|
DDI-MedLine.d94.s12.p1
|
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
|
sodium nitroprusside
|
INOmax
|
EFFECT
|
Nitric Oxide_ddi.xml
|
DDI-DrugBank.d183.s2
|
DDI-DrugBank.d183.s2.p4
|
Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
|
rifabutin
|
CRIXIVAN
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s84
|
DDI-DrugBank.d97.s84.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
oxcarbazepine
|
quetiapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p933
|
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
|
Rifampin
|
rifampin
|
NONE
|
11158747.xml
|
DDI-MedLine.d3.s8
|
DDI-MedLine.d3.s8.p2
|
Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
|
reserpine
|
beta blocking agents
|
EFFECT
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s0
|
DDI-DrugBank.d422.s0.p0
|
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
|
Antihistamines
|
CNS depressants
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s0
|
DDI-DrugBank.d389.s0.p3
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
ciprofloxacin
|
aluminum
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p21
|
Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
|
antacids
|
lactulose
|
MECHANISM
|
Lactulose_ddi.xml
|
DDI-DrugBank.d206.s0
|
DDI-DrugBank.d206.s0.p0
|
Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
|
bosentan
|
R-warfarin
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s30
|
DDI-DrugBank.d289.s30.p4
|
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
|
Ibogaine
|
morphine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s9
|
DDI-MedLine.d110.s9.p1
|
Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
|
digoxin
|
Itraconazole
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s16
|
DDI-DrugBank.d165.s16.p5
|
no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
|
pravastatin
|
diltiazem
|
NONE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s38
|
DDI-DrugBank.d565.s38.p0
|
Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
|
tiagabine
|
carbamazepine
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s10
|
DDI-DrugBank.d277.s10.p12
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
niacin
|
estrogens
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p24
|
Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
|
antidiabetic agents
|
VELCADE
|
ADVISE
|
Bortezomib_ddi.xml
|
DDI-DrugBank.d571.s4
|
DDI-DrugBank.d571.s4.p0
|
Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
|
BREVIBLOC
|
verapamil
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s13
|
DDI-DrugBank.d422.s13.p0
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine hydrochloride
|
hypnotics
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p3
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
thiazide diuretics
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p17
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
lithium
|
insulin
|
EFFECT
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s3
|
DDI-DrugBank.d313.s3.p8
|
Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
|
Rifampin
|
warfarin
|
MECHANISM
|
1115445.xml
|
DDI-MedLine.d116.s2
|
DDI-MedLine.d116.s2.p0
|
Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45 (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
|
Beta Blockers
|
ergotamine
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s3
|
DDI-DrugBank.d410.s3.p4
|
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
|
progestin
|
carbamazepine
|
EFFECT
|
Norethindrone_ddi.xml
|
DDI-DrugBank.d306.s0
|
DDI-DrugBank.d306.s0.p2
|
Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
|
beta-adrenergic blockers
|
digoxin
|
EFFECT
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s12
|
DDI-DrugBank.d450.s12.p1
|
Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
|
piperacillin
|
aminoglycoside
|
EFFECT
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s0
|
DDI-DrugBank.d462.s0.p3
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
foscarnet
|
zalcitabine
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p24
|
Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
|
cimetidine
|
Xanax
|
ADVISE
|
Adinazolam_ddi.xml
|
DDI-DrugBank.d449.s1
|
DDI-DrugBank.d449.s1.p5
|
Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
|
Lamivudine
|
zalcitabine
|
EFFECT
|
Lamivudine_ddi.xml
|
DDI-DrugBank.d71.s5
|
DDI-DrugBank.d71.s5.p0
|
Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
|
dicyclomine
|
cisapride
|
EFFECT
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s3
|
DDI-DrugBank.d237.s3.p9
|
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
|
non-potassium sparing diuretics
|
beta-agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s4
|
DDI-DrugBank.d284.s4.p2
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
|
ergot-type medications
|
AXERT
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s1
|
DDI-DrugBank.d299.s1.p6
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
pertechnetate
|
mitotane
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p200
|
At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
|
VIOXX
|
methotrexate
|
MECHANISM
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s20
|
DDI-DrugBank.d210.s20.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
antifungals
|
phenylbutazone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p516
|
Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
|
indomethacin
|
potassium-sparing diuretics
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s6
|
DDI-DrugBank.d356.s6.p0
|
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
|
beta-adrenergic blocking agents
|
calcium antagonist
|
EFFECT
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s4
|
DDI-DrugBank.d252.s4.p1
|
Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
|
Potassium-Sparing Diuretics
|
thiazide diuretics
|
EFFECT
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s3
|
DDI-DrugBank.d561.s3.p2
|
Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
|
theophylline
|
sympathomimetic bronchodilators
|
EFFECT
|
Dyphylline_ddi.xml
|
DDI-DrugBank.d4.s0
|
DDI-DrugBank.d4.s0.p4
|
Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
|
Enoxacin
|
methylxanthines
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s20
|
DDI-DrugBank.d395.s20.p2
|
Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
|
acitretin
|
ethanol
|
MECHANISM
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s0
|
DDI-DrugBank.d353.s0.p5
|
Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
|
Imipramine hydrochloride
|
CNS depressant drugs
|
EFFECT
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s4
|
DDI-DrugBank.d77.s4.p0
|
Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
|
valdecoxib
|
dextromethorphan
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s18
|
DDI-DrugBank.d328.s18.p0
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
epinephrine
|
tricyclic antidepressants
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s0
|
DDI-DrugBank.d564.s0.p6
|
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
|
clozapine
|
fluoxetine
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s22
|
DDI-DrugBank.d480.s22.p2
|
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
|
rifabutin
|
ofloxacin
|
EFFECT
|
11137650.xml
|
DDI-MedLine.d8.s6
|
DDI-MedLine.d8.s6.p9
|
Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45 (dihydroergotamine mesylate) Injection, USP has not been studied.
|
Contraceptives
|
D.H.E. 45
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s10
|
DDI-DrugBank.d410.s10.p1
|
Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
|
Clozapine
|
antihypertensive drugs
|
EFFECT
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s9
|
DDI-DrugBank.d480.s9.p0
|
Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
|
L-phenylalanine
|
selegiline
|
EFFECT
|
L-Phenylalanine_ddi.xml
|
DDI-DrugBank.d530.s2
|
DDI-DrugBank.d530.s2.p4
|
If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
|
chlorprothixene
|
opioids
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s2
|
DDI-DrugBank.d503.s2.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
tetracyclines
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p2
|
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
|
phenobarbital
|
acetaminophen
|
EFFECT
|
11206047.xml
|
DDI-MedLine.d111.s14
|
DDI-MedLine.d111.s14.p9
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
antihistamines
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p6
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
benzodiazepines
|
narcotics
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p1
|
Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
|
tricyclic
|
sympathomimetic agents
|
NONE
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s7
|
DDI-DrugBank.d236.s7.p9
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
5-fluorouracil
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p6
|
Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
|
terfenadine
|
astemizole
|
NONE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s10
|
DDI-DrugBank.d397.s10.p5
|
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
|
diclofenac
|
aspirin
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s0
|
DDI-DrugBank.d249.s0.p6
|
When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
|
phenobarbital
|
Nalfon
|
ADVISE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s4
|
DDI-DrugBank.d154.s4.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
acetaminophen
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p0
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
Sucralfate
|
didanosine
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p19
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cimetidine
|
dextrothyroxine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p542
|
Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
|
verapamil
|
dofetilide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s7
|
DDI-DrugBank.d558.s7.p4
|
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
|
temazepam
|
ethanol
|
MECHANISM
|
9120829.xml
|
DDI-MedLine.d113.s3
|
DDI-MedLine.d113.s3.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
felodipine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p17
|
Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
Videx
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s12
|
DDI-DrugBank.d217.s12.p1
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
alcohol
|
insulin
|
EFFECT
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s3
|
DDI-DrugBank.d527.s3.p9
|
Therefore, concomitant use of TORADOL and probenecid is contraindicated.
|
TORADOL
|
probenecid
|
ADVISE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s10
|
DDI-DrugBank.d3.s10.p0
|
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
|
8-phenyltheophylline
|
8-cyclopentyl-1,3-dipropylxanthine
|
NONE
|
7746025.xml
|
DDI-MedLine.d51.s1
|
DDI-MedLine.d51.s1.p7
|
Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
|
amantadine
|
central nervous system stimulants
|
ADVISE
|
Amantadine_ddi.xml
|
DDI-DrugBank.d116.s0
|
DDI-DrugBank.d116.s0.p0
|
Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
|
temazepam
|
ethanol
|
MECHANISM
|
9120829.xml
|
DDI-MedLine.d113.s0
|
DDI-MedLine.d113.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
mirtazapine
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p880
|
Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
|
naltrexone
|
Acamprosate
|
MECHANISM
|
Acamprosate_ddi.xml
|
DDI-DrugBank.d0.s2
|
DDI-DrugBank.d0.s2.p0
|
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
|
sulphonylureas
|
Bezalip
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s3
|
DDI-DrugBank.d291.s3.p1
|
Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
|
Probenecid
|
cephalosporins
|
MECHANISM
|
Cefazolin_ddi.xml
|
DDI-DrugBank.d281.s0
|
DDI-DrugBank.d281.s0.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Invirase
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p27
|
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
|
Bosentan
|
atorvastatin
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s27
|
DDI-DrugBank.d289.s27.p2
|
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
|
EPA
|
Ginkgo biloba
|
INT
|
Icosapent_ddi.xml
|
DDI-DrugBank.d35.s0
|
DDI-DrugBank.d35.s0.p3
|
Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
|
flurbiprofen
|
furosemide
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s14
|
DDI-DrugBank.d529.s14.p4
|
Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
|
Anticoagulants
|
cefixime
|
EFFECT
|
Cefixime_ddi.xml
|
DDI-DrugBank.d339.s2
|
DDI-DrugBank.d339.s2.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
troleandomycin
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p345
|
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
|
Cimetidine
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s10
|
DDI-DrugBank.d237.s10.p4
|
INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
|
INDOCIN
|
digoxin
|
MECHANISM
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s21
|
DDI-DrugBank.d82.s21.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
valproate
|
verapamil
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p348
|
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
|
famotidine
|
lansoprazole
|
NONE
|
Diatrizoate_ddi.xml
|
DDI-DrugBank.d293.s0
|
DDI-DrugBank.d293.s0.p28
|
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
|
beta-adrenoceptor blocking agents
|
nonsteroidal anti-inflammatory drugs
|
EFFECT
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s4
|
DDI-DrugBank.d388.s4.p0
|
The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
|
quinolones
|
glyburide
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s7
|
DDI-DrugBank.d217.s7.p1
|
- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
|
Lofexidine
|
sedatives
|
EFFECT
|
Lofexidine_ddi.xml
|
DDI-DrugBank.d454.s0
|
DDI-DrugBank.d454.s0.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clonazepam
|
glucocorticoids
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p342
|
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
|
Rifampin
|
amprenavir
|
MECHANISM
|
11158747.xml
|
DDI-MedLine.d3.s8
|
DDI-MedLine.d3.s8.p0
|
Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
|
methotrexate
|
methotrexate
|
NONE
|
L-Methionine_ddi.xml
|
DDI-DrugBank.d528.s0
|
DDI-DrugBank.d528.s0.p6
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
furosemide
|
EFFECT
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s6
|
DDI-DrugBank.d400.s6.p3
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
didanosine
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p10
|
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
|
EPA
|
ginkgo
|
INT
|
Icosapent_ddi.xml
|
DDI-DrugBank.d35.s0
|
DDI-DrugBank.d35.s0.p2
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
polymyxins
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p5
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
disopyramide
|
fibrates
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p19
|
Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
|
EULEXIN
|
warfarin
|
ADVISE
|
Flutamide_ddi.xml
|
DDI-DrugBank.d442.s1
|
DDI-DrugBank.d442.s1.p2
|
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
|
levetiracetam
|
AEDs
|
MECHANISM
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s13
|
DDI-DrugBank.d212.s13.p2
|
The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
|
sodium nitroprusside
|
hypotensive drugs
|
EFFECT
|
Nitroprusside_ddi.xml
|
DDI-DrugBank.d394.s0
|
DDI-DrugBank.d394.s0.p0
|
Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
|
L-methionine
|
methotrexate
|
EFFECT
|
L-Methionine_ddi.xml
|
DDI-DrugBank.d528.s0
|
DDI-DrugBank.d528.s0.p8
|
Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
|
Phenobarbital
|
Amphetamines
|
NONE
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s23
|
DDI-DrugBank.d236.s23.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.